PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, rest of Asia, Europe, Australia, Africa, and New Zealand. More Details
Moderate growth potential and overvalued.
Share Price & News
How has Kimia Farma (Persero)'s share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KAEF is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: KAEF's weekly volatility has decreased from 13% to 8% over the past year.
7 Day Return
1 Year Return
Return vs Industry: KAEF exceeded the ID Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: KAEF exceeded the ID Market which returned 22.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Kimia Farma (Persero)'s share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Kimia Farma (Persero) undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: KAEF (IDR2660) is trading above our estimate of fair value (IDR468.59)
Significantly Below Fair Value: KAEF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: KAEF is poor value based on its PE Ratio (837.6x) compared to the ID Pharmaceuticals industry average (25x).
PE vs Market: KAEF is poor value based on its PE Ratio (837.6x) compared to the ID market (22.4x).
Price to Earnings Growth Ratio
PEG Ratio: KAEF is poor value based on its PEG Ratio (11.8x)
Price to Book Ratio
PB vs Industry: KAEF is good value based on its PB Ratio (2.1x) compared to the ID Pharmaceuticals industry average (2.4x).
How is Kimia Farma (Persero) forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KAEF's forecast earnings growth (70.9% per year) is above the savings rate (7.2%).
Earnings vs Market: KAEF's earnings (70.9% per year) are forecast to grow faster than the ID market (21.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: KAEF's revenue (4.5% per year) is forecast to grow slower than the ID market (10.7% per year).
High Growth Revenue: KAEF's revenue (4.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KAEF's Return on Equity is forecast to be low in 3 years time (1.9%).
How has Kimia Farma (Persero) performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KAEF has a large one-off gain of IDR16.2B impacting its December 31 2020 financial results.
Growing Profit Margin: KAEF became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: KAEF's earnings have declined by 19% per year over the past 5 years.
Accelerating Growth: KAEF has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: KAEF has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).
Return on Equity
High ROE: KAEF's Return on Equity (0.3%) is considered low.
How is Kimia Farma (Persero)'s financial position?
Financial Position Analysis
Short Term Liabilities: KAEF's short term assets (IDR6,093.1B) do not cover its short term liabilities (IDR6,786.9B).
Long Term Liabilities: KAEF's short term assets (IDR6,093.1B) exceed its long term liabilities (IDR3,670.2B).
Debt to Equity History and Analysis
Debt Level: KAEF's debt to equity ratio (108.6%) is considered high.
Reducing Debt: KAEF's debt to equity ratio has increased from 15.7% to 108.6% over the past 5 years.
Debt Coverage: KAEF's debt is not well covered by operating cash flow (13.2%).
Interest Coverage: KAEF's interest payments on its debt are not well covered by EBIT (1.1x coverage).
What is Kimia Farma (Persero) current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KAEF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KAEF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KAEF's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KAEF's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: KAEF is not paying a notable dividend for the ID market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KAEF's dividend in 3 years as they are not forecast to pay a notable one for the ID market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Verdi Budidarmo (51 yo)
Dr. Verdi Budidarmo serves as President Director at PT Kimia Farma (Persero) Tbk since September 18, 2019. He serves as President Commissioner at PT Phapros Tbk since August 26, 2019. He has been Operation...
Experienced Management: KAEF's management team is considered experienced (2.3 years average tenure).
Experienced Board: KAEF's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PT Kimia Farma (Persero) Tbk's company bio, employee growth, exchange listings and data sources
- Name: PT Kimia Farma (Persero) Tbk
- Ticker: KAEF
- Exchange: IDX
- Founded: 1817
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: Rp14.774t
- Shares outstanding: 5.55b
- Website: https://kimiafarma.co.id
Number of Employees
- PT Kimia Farma (Persero) Tbk
- Jl. Veteran No.9
- Jakarta Raya
PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, rest of Asia, Europe, Australia, Africa, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 18:23|
|End of Day Share Price||2021/05/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.